Zepbound reported $517.4 million in sales for the quarter, even as most doses of the drug slipped into shortages in the U.S.
The company also hiked its full-year guidance on strong sales of its blockbuster diabetes drug Mounjaro and newly launched weight loss treatment Zepbound.
The drugmaker now expects full-year adjusted earnings of $13.50 to $14.00 per share, up from a previous guidance of $12.20 to $12.70 per share. Eli Lilly also expects revenue for the year to come in between $42.4 billion and $43.6 billion, an increase of $2 billion at either end of the range. The results and guidance raise reflect Zepbound's first full quarter on the U.S. market after winning approval from regulators in early November. The drug reported $517.4 million in sales for the first quarter, even as most doses of the drugAnalysts say the weekly injection could post more than a billion dollars in sales in its first year on the market and potentially become theEli Lilly posted a net income of $2.24 billion, or $2.48 a share, for the first quarter.
Biotechnology Biotech And Pharmaceuticals Pharmaceuticals Health Care Industry Earnings Breaking News Eli Lilly And Co United States Business News
France Dernières Nouvelles, France Actualités
Similar News:Vous pouvez également lire des articles d'actualité similaires à celui-ci que nous avons collectés auprès d'autres sources d'information.
Eli Lilly beats on quarterly profit, hikes full-year guidance on strong sales of Zepbound, MounjaroZepbound reported $517.4 million in sales for the quarter, even as most doses of the drug slipped into shortages in the U.S.
Lire la suite »
Most doses of Eli Lilly's Zepbound, Mounjaro in short supply through June, FDA saysThe insatiable demand for weight loss and diabetes drugs is still trouncing supply, even as Eli Lilly and Novo Nordisk work to increase production capacity.
Lire la suite »
Most of Lilly's Mounjaro and Zepbound doses in limited supply, FDA saysMost doses of Eli Lilly's diabetes drug Mounjaro and weight-loss drug Zepbound would be in limited supply through the second quarter of this year due to increased demand, the U.S. Food and Drug Administration's website showed on Wednesday.
Lire la suite »
Eli Lilly's weight-loss drug Zepbound could treat sleep apneaAn FDA green light could mean broader insurance coverage and a new treatment for a condition affecting 20 million Americans.
Lire la suite »
Zepbound weight loss drug shortage has no immediate end in sight, Eli Lilly saysBerkeley Lovelace Jr. is a health and medical reporter for NBC News. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. He previously covered the biotech and pharmaceutical industry with CNBC.
Lire la suite »
Eli Lilly’s weight loss drug Zepbound found to reduce sleep apnea, company saysBerkeley Lovelace Jr. is a health and medical reporter for NBC News. He covers the Food and Drug Administration, with a special focus on Covid vaccines, prescription drug pricing and health care. He previously covered the biotech and pharmaceutical industry with CNBC.
Lire la suite »